Sanara MedTech Q4 2025 Preview: $27.4M Revenue, $0.11 EPS Estimates
Sanara MedTech will report Q4 2025 results on March 24 with expected revenue of $27.40 million and earnings of $0.11 per share, and full-year 2025 forecasts of $102.55 million in revenue and $0.20 EPS. Over the past 90 days, 2025 revenue estimates fell from $103.33 million to $102.55 million while EPS forecasts climbed from -$0.98 to $0.20.
1. Q4 2025 Guidance
Sanara MedTech will publish Q4 2025 results on March 24 with consensus estimates of $27.40 million in revenue and $0.11 earnings per share. Full-year 2025 forecasts stand at $102.55 million in revenue and $0.20 EPS, reflecting modest growth expectations from prior periods.
2. Estimate Revisions
Over the past 90 days, full-year 2025 revenue projections declined from $103.33 million to $102.55 million and 2026 revenue estimates slipped from $120.58 million to $118.60 million. In contrast, earnings estimates improved significantly, with 2025 EPS rising from -$0.98 to $0.20 and 2026 EPS climbing from -$0.50 to $0.65.
3. Historical Performance
In Q3 2025, Sanara MedTech reported $26.33 million in revenue, missing the $26.63 million consensus by 1.09%, and posted a loss of $3.52 per share versus expectations of -$0.22. Shares fell 24.71% the day after the results were announced.
4. Analyst Price Targets
One analyst sets a one-year target of $36.00, implying a 95.9% upside, while a proprietary valuation model projects $54.73, or nearly 198% upside. The average brokerage recommendation is 2.0, equivalent to an 'Outperform' rating.